Skip to main content
. Author manuscript; available in PMC: 2022 Oct 11.
Published in final edited form as: Cancer Cell. 2021 Aug 19;39(10):1375–1387.e6. doi: 10.1016/j.ccell.2021.07.023

Figure 1. Progression-free survival of patients with BRAFV600MUT melanoma treated with dabrafenib plus trametinib and stratified by prior exposure to ICT.

Figure 1.

Results from the S1320 SWOG trial and analyzed by the univariate Cox regression model. ICT, immune checkpoint therapy.

See also Figure S1, Table S1, S2A and S2B.